4-(((5-甲氧基-5-氧代戊基)(2-((4-苯乙基苄基)氧基)苯乙基)氨基)甲基)苯甲 | 329773-33-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 4-(((5-甲氧基-5-氧代戊基)(2-((4-苯乙基苄基)氧基)苯乙基)氨基)甲基)苯甲
• 英文名称: methyl 4-(((5-methoxy-5-oxopentyl)(2-((4-phenethylbenzyl)oxy)phenethyl)amino)methyl)benzoate
• 英文别名: methyl 4-[[(5-methoxy-5-oxopentyl)-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoate
• CAS: 329773-33-3
• 化学式: C₃₈H₄₃NO₅
• 分子量: 593.763
• InChiKey: OWCHLQYUTRTNRI-UHFFFAOYSA-N

物化性质

• 沸点：
  680.5±55.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  44
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(((5-甲氧基-5-氧代戊基)(2-((4-苯乙基苄基)氧基)苯乙基)氨基)甲基)苯甲 在 sodium hydroxide 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 以92%的产率得到4-[[(4-carboxybutyl)-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid hydrochloride
  参考文献：
  名称：

  Insights into Soluble Guanylyl Cyclase Activation Derived from Improved Heme-Mimetics

  摘要：

  Recently, the structure of BAY 58-2667 bound to the Nostoc sp. H-NOX domain was published. On the basis of this structural information, we designed BAY 58-2667 derivatives and tested their effects on soluble guanylyl cyclase (sGC) activity. Derivative 20 activated sGC 4.8-fold more than BAY 58-2667. Co-crystallization of 20 with the Ns H-NOX domain revealed that the increased conformational distortion at the C-terminal region of alpha F helix containing 110-114 residues contributes to the higher activation triggered by 20.

  DOI：

  10.1021/jm400539d
• 作为产物：
  描述：

  methyl 4-((5-methoxy-5-oxo-N-(2-((4-phenethylbenzyl)oxy)phenethyl)pentanamido)methyl)benzoate 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以54%的产率得到4-(((5-甲氧基-5-氧代戊基)(2-((4-苯乙基苄基)氧基)苯乙基)氨基)甲基)苯甲
  参考文献：
  名称：

  Insights into Soluble Guanylyl Cyclase Activation Derived from Improved Heme-Mimetics

  摘要：

  Recently, the structure of BAY 58-2667 bound to the Nostoc sp. H-NOX domain was published. On the basis of this structural information, we designed BAY 58-2667 derivatives and tested their effects on soluble guanylyl cyclase (sGC) activity. Derivative 20 activated sGC 4.8-fold more than BAY 58-2667. Co-crystallization of 20 with the Ns H-NOX domain revealed that the increased conformational distortion at the C-terminal region of alpha F helix containing 110-114 residues contributes to the higher activation triggered by 20.

  DOI：

  10.1021/jm400539d

文献信息

• Labelling of the guanylate cyclase activator cinaciguat (BAY 58-2667) with carbon-14, tritium and stable isotopes
  作者：D. Seidel、U. Pleiß

  DOI：10.1002/jlcr.1738

  日期：2010.3

  For studies of pharmacokinetics and drug metabolism of the new soluble guanylate cyclase activator cinaciguat (BAY 58-2667) the 14C-labelled compound was synthesized. The tritiated compound was required to elucidate the mode of action and the stable labelled compound was required for bio-analytical studies by quantitative mass spectrometry as well. Two radiosyntheses are described with different formation of the labelled intermediate 1-(chloro[14C]methyl)-4-(2-phenylethyl)benzene. The first one started with 14C-carboxylation of 1-bromo-4-(2-phenylethyl)benzene yielding the desired product in 5 steps. In the second synthesis intermediate 1-(chloro[14C]methyl)-4-(2-phenylethyl)benzene was formed by chloromethylation of bibenzyl with [14C]paraformaldehyde/hydrochloric acid subsequently resulting in the final product in three steps. Tritium labelling was performed by tritium exchange of the diester intermediate using an organo-iridium catalyst and subsequent saponification. The stable labelled compound was synthesized via a convergent synthesis starting with 13C,15N-cyanation of 1-(chloromethyl)-2-[4-(2-phenylethyl)benzyl]oxy}benzene and 13C-cyanation of methyl 4-bromobenzoate, respectively. The labelled product was obtained after 7 chemical steps. Copyright © 2010 John Wiley & Sons, Ltd.

  为了研究新型可溶性鸟苷酸环化酶激活剂西那西瓜酯（BAY 58-2667）的药代动力学和药物代谢，合成了 14C 标记的化合物。需要三价化合物来阐明其作用模式，还需要稳定的标记化合物来进行定量质谱生物分析研究。本文介绍了两种放射性合成方法，其标记中间体 1-(氯[14C]甲基)-4-(2-苯基乙基)苯的形成过程各不相同。第一种合成是从 1-溴-4-(2-苯基乙基)苯的 14C 羧化开始，经过 5 个步骤得到所需的产物。在第二种合成方法中，中间体 1-(氯[14C]甲基)-4-(2-苯基乙基)苯是通过氯甲基化联苄与[14C]多聚甲醛/盐酸反应形成的，随后经过三个步骤得到最终产物。使用有机铱催化剂对二酯中间体进行氚交换，然后进行皂化，从而进行氚标记。稳定的标记化合物是分别从 1-(氯甲基)-2-[4-(2-苯基乙基)苄基]氧基}苯的 13C、15N-氰化反应和 4-溴苯甲酸甲酯的 13C 氰化反应开始，通过聚合合成法合成的。经过 7 个化学步骤后得到了标记产品。Copyright © 2010 John Wiley & Sons, Ltd. All Rights Reserved.
• Aminodicarboxylic acid derivatives having pharmaceutical properties
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：US07781470B2

  公开（公告）日：2010-08-24

  The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

  本发明涉及以下式子的化合物（II），（IV）和（VI），其中各个变量组在规范和索赔中定义。还公开了制备这些材料的过程，以及在合成用于治疗心血管疾病和纤维化疾病的化合物的方法。
• Novel aminodicarboxylic acid derivatives having pharmaceutical properties
  申请人：Alonso-Alija Cristina

  公开号：US20060094769A1

  公开（公告）日：2006-05-04

  The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

  本发明涉及以下式子（II），（IV）和（VI）的化合物，其中各个变量基团如规范和要求中所定义。还公开了制备这些材料的过程以及将它们用于合成治疗心血管疾病和纤维化疾病的化合物的方法。
• NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES
  申请人：Alonso-Alija Cristina

  公开号：US20100317854A1

  公开（公告）日：2010-12-16

  The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

  本发明涉及以下式子的化合物（II），（IV）和（VI），其中各个变量组在规范和要求中定义。还公开了制备这些材料的过程，以及在合成用于治疗心血管疾病和纤维化疾病的化合物的方法。
• Derivatives of dicarboxylic acid having pharmaceutical properties
  申请人：Bayer Aktiengesellschaft

  公开号：US07087644B1

  公开（公告）日：2006-08-08

  The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, pharmaceutical compositions containing them, and methods for using them for treatment of cardiovascular disorders are also disclosed and claimed.

  本发明涉及式（I）的化合物，以及其盐和立体异构体，其中几个变量基团如规范和权利要求所定义的那样。本发明还揭示和声明制备这些材料的过程，包含它们的药物组合物以及使用它们治疗心血管疾病的方法。